PANCREATIC CANCER PROTOCOLS
If you or someone you know has been diagnosed with pancreatic cancer and surgery is not an option, consider a new clinical research trial that is delivering chemotherapy in an innovative way.
The trial combines the benefits of standard-of-care therapy with a targeted treatment approach to reach more tumor cells.
Patients will receive chemotherapy in 2 ways:
1. Direct infusion of oxaliplatin with the proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach with SmartValve™ technology, to deliver targeted therapy directly into the tumor.
2. Systemic infusion, which is the traditional way of receiving chemotherapy.
Systemic infusion of chemotherapy is an important part of treatment, but due to the tumor's dense structure and poor blood flow, therapy doesn't always get into the tumor. Direct infusion with the PEDD approach with SmartValue technology is designed to overcome those barriers.
If you are interested in learning more about this clinical trial, please contact:
Kimberly Enos, FNP at (401-456-6472) or email at Kimberly.email@example.com
You can also visit the website for the trial here.